Associate Professor of Radiology
Associate Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail
Dept of Radiology, Box 3808, Durham, NC 27710
Phone
(919) 684-7366
Email address
mustafa.bashir@duke.edu
Hepatobiliary and pancreatic imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Education and Training
- M.D., University of Iowa, 2004
Grants
- Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
- A Phase 1b, Open-Label, Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients with Presumed Nonalcoholic Steatohepatitis (NASH)
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
- BIO89-100-122 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
- A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients with Presumed Nonalcoholic Steatohepatitis
- The imaging objectives of this study are to determine the effect of MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population for the following:
- The imaging objective of this study is to determine the effect of MET642 on liver PDFF in patients with nonalcoholic steatohepatitis (NASH).
- CT-868 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Obese Patients wi
- Collaboration for assessment of 129Xe MRI hardware
- Abbreviated MRI for HCC screening in cirrhotic patients
- Madrigal MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or
- A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH)"
- Determine the effect of GH509 on liver PDFF in a NASH population
- Madrigal MGL-3196-14 "A 52-Week Phase 3 Study of Resmetirom (MGL-3196)
- Imaging Core Lab for Madrigal Protocol MGL-3196-05 (A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis)